Treatment for Patients Unsuitable for or Refractory to Consolidation Durvalumab
August 3rd 2023
Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.